HEADER TRANSFERASE 31-MAY-02 1LWC TITLE CRYSTAL STRUCTURE OF M184V MUTANT HIV-1 REVERSE TRANSCRIPTASE IN TITLE 2 COMPLEX WITH NEVIRAPINE COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 REVERSE TRANSCRIPTASE; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: P66; COMPND 5 SYNONYM: HIV-1 RT; COMPND 6 EC: 2.7.7.49; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: HIV-1 REVERSE TRANSCRIPTASE; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: P51; COMPND 13 SYNONYM: HIV-1 RT; COMPND 14 EC: 2.7.7.49; COMPND 15 ENGINEERED: YES; COMPND 16 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: HIV-1 POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: TG-1; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PKK233-2; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 12 ORGANISM_TAXID: 11676; SOURCE 13 GENE: HIV-1 POL; SOURCE 14 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 15 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 16 EXPRESSION_SYSTEM_STRAIN: TG-1; SOURCE 17 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PKK233-2 KEYWDS HIV-1 REVERSE TRANSCRIPTASE, AIDS, AZT, 3TC, NRTI, NEVIRAPINE, DRUG KEYWDS 2 RESISTANCE MUTATIONS, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR J.REN,P.P.CHAMBERLAIN,C.E.NICHOLS,L.DOUGLAS,D.I.STUART,D.K.STAMMERS REVDAT 4 20-NOV-24 1LWC 1 REMARK REVDAT 3 10-NOV-21 1LWC 1 REMARK SEQADV LINK REVDAT 2 24-FEB-09 1LWC 1 VERSN REVDAT 1 30-OCT-02 1LWC 0 JRNL AUTH P.P.CHAMBERLAIN,J.REN,C.E.NICHOLS,L.DOUGLAS,J.LENNERSTRAND, JRNL AUTH 2 B.A.LARDER,D.I.STUART,D.K.STAMMERS JRNL TITL CRYSTAL STRUCTURES OF ZIDOVUDINE- OR LAMIVUDINE-RESISTANT JRNL TITL 2 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 REVERSE TRANSCRIPTASES JRNL TITL 3 CONTAINING MUTATIONS AT CODONS 41, 184, AND 215. JRNL REF J.VIROL. V. 76 10015 2002 JRNL REFN ISSN 0022-538X JRNL PMID 12208978 JRNL DOI 10.1128/JVI.76.19.10015-10019.2002 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.REN,C.E.NICHOLS,L.E.BIRD,P.CHAMBERLAIN,K.L.WEAVER, REMARK 1 AUTH 2 S.A.SHORT,D.I.STUART,D.K.STAMMERS REMARK 1 TITL STRUCTURAL MECHANISMS OF DRUG RESISTANCE FOR MUTATIONS AT REMARK 1 TITL 2 CODONS 181 AND 188 IN HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 IMPROVED RESILIENCE OF SECOND GENERATION NON-NUCLEOSIDE REMARK 1 TITL 4 INHIBITORS REMARK 1 REF J.MOL.BIOL. V. 312 795 2001 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.2001.4988 REMARK 1 REFERENCE 2 REMARK 1 AUTH J.H.CHAN,J.S.HONG,R.N.HUNTER III,G.F.ORR,J.R.COWAN, REMARK 1 AUTH 2 D.B.SHERMAN,S.M.SPARKS,B.E.REITTER,C.W.ANDREWS III, REMARK 1 AUTH 3 R.J.HAZEN,M.ST CLAIR,L.R.BOONE,R.G.FERRIS,K.L.CREECH, REMARK 1 AUTH 4 G.B.ROBERTS,S.A.SHORT,K.L.WEAVER,R.J.OTT,J.REN,A.L.HOPKINS, REMARK 1 AUTH 5 D.I.STUART,D.K.STAMMERS REMARK 1 TITL 2-AMINO-6-ARYLSULFONYLBENZONITRILES AS NON-NUCLEOSIDE REMARK 1 TITL 2 REVERSE TRANSCRIPTASE INHIBITORS OF HIV-1 REMARK 1 REF J.MED.CHEM. V. 44 1866 2001 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM0004906 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.REN,J.MILTON,K.L.WEAVER,S.A.SHORT,D.I.STUART,D.K.STAMMERS REMARK 1 TITL STRUCTURAL BASIS FOR THE RESILIENCE OF EFAVIRENZ (DMP-266) REMARK 1 TITL 2 TO DRUG RESISTANCE MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE REMARK 1 REF STRUCTURE V. 8 1089 2000 REMARK 1 REFN ISSN 0969-2126 REMARK 1 DOI 10.1016/S0969-2126(00)00513-X REMARK 1 REFERENCE 4 REMARK 1 AUTH J.REN,C.E.NICHOLS,L.E.BIRD,T.FUJIWARA,H.SUGIMOTO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL BINDING OF THE SECOND GENERATION NON-NUCLEOSIDE INHIBITOR REMARK 1 TITL 2 S-1153 TO HIV-1 REVERSE TRANSCRIPTASE INVOLVES EXTENSIVE REMARK 1 TITL 3 MAIN CHAIN HYDROGEN BONDING REMARK 1 REF J.BIOL.CHEM. V. 275 14316 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.19.14316 REMARK 1 REFERENCE 5 REMARK 1 AUTH J.REN,J.DIPROSE,J.WARREN,R.M.ESNOUF,L.E.BIRD,S.IKEMIZU, REMARK 1 AUTH 2 M.SLATER,J.MILTON,J.BALZARINI,D.I.STUART,D.K.STAMMERS REMARK 1 TITL PHENETHYLTHIAZOLYLTHIOUREA (PETT) NON-NUCLEOSIDE INHIBITORS REMARK 1 TITL 2 OF HIV-1 AND HIV-2 REVERSE TRANSCRIPTASES. STRUCTURAL AND REMARK 1 TITL 3 BIOCHEMICAL ANALYSES REMARK 1 REF J.BIOL.CHEM. V. 275 5633 2000 REMARK 1 REFN ISSN 0021-9258 REMARK 1 DOI 10.1074/JBC.275.8.5633 REMARK 1 REFERENCE 6 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTALLOGRAPHIC ANALYSIS OF THE BINDING MODES OF REMARK 1 TITL 2 THIAZOLOISOINDOLINONE NON-NUCLEOSIDE INHIBITORS TO HIV-1 REMARK 1 TITL 3 REVERSE TRANSCRIPTASE AND COMPARISON WITH MODELING STUDIES REMARK 1 REF J.MED.CHEM. V. 42 3845 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990275T REMARK 1 REFERENCE 7 REMARK 1 AUTH A.L.HOPKINS,J.REN,H.TANAKA,M.BABA,M.OKAMATO,D.I.STUART, REMARK 1 AUTH 2 D.K.STAMMERS REMARK 1 TITL DESIGN OF MKC-442 (EMIVIRINE) ANALOGUES WITH IMPROVED REMARK 1 TITL 2 ACTIVITY AGAINST DRUG-RESISTANT HIV MUTANTS REMARK 1 REF J.MED.CHEM. V. 42 4500 1999 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM990192C REMARK 1 REFERENCE 8 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,J.WARREN,J.BALZARINI, REMARK 1 AUTH 2 D.I.STUART,D.K.STAMMERS REMARK 1 TITL CRYSTAL STRUCTURES OF HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX REMARK 1 TITL 2 WITH CARBOXANILIDE DERIVATIVES REMARK 1 REF BIOCHEMISTRY V. 37 14394 1998 REMARK 1 REFN ISSN 0006-2960 REMARK 1 DOI 10.1021/BI981309M REMARK 1 REFERENCE 9 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,E.Y.JONES,I.KIRBY,J.KEELING, REMARK 1 AUTH 2 C.K.ROSS,B.A.LARDER,D.I.STUART,D.K.STAMMERS REMARK 1 TITL 3'-AZIDO-3'-DEOXYTHYMIDINE DRUG RESISTANCE MUTATIONS IN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CAN INDUCE LONG RANGE REMARK 1 TITL 3 CONFORMATIONAL CHANGES REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 95 9518 1998 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.95.16.9518 REMARK 1 REFERENCE 10 REMARK 1 AUTH R.M.ESNOUF,J.REN,E.F.GARMAN,D.O.SOMERS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL CONTINUOUS AND DISCONTINUOUS CHANGES IN THE UNIT CELL OF REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE CRYSTALS ON DEHYDRATION REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 54 938 1998 REMARK 1 REFN ISSN 0907-4449 REMARK 1 DOI 10.1107/S0907444998004284 REMARK 1 REFERENCE 11 REMARK 1 AUTH R.M.ESNOUF,J.REN,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL UNIQUE FEATURES IN THE STRUCTURE OF THE COMPLEX BETWEEN REMARK 1 TITL 2 HIV-1 REVERSE TRANSCRIPTASE AND THE REMARK 1 TITL 3 BIS(HETEROARYL)PIPERAZINE (BHAP) U-90152 EXPLAIN RESISTANCE REMARK 1 TITL 4 MUTATIONS FOR THIS NON-NUCLEOSIDE INHIBITOR REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 94 3984 1997 REMARK 1 REFN ISSN 0027-8424 REMARK 1 DOI 10.1073/PNAS.94.8.3984 REMARK 1 REFERENCE 12 REMARK 1 AUTH A.L.HOPKINS,J.REN,R.M.ESNOUF,B.E.WILLCOX,E.Y.JONES,C.K.ROSS, REMARK 1 AUTH 2 T.MIYASAKA,R.T.WALKER,H.TANAKA,D.K.STAMMERS,D.I.STUART REMARK 1 TITL COMPLEXES OF HIV-1 REVERSE TRANSCRIPTASE WITH INHIBITORS OF REMARK 1 TITL 2 THE HEPT SERIES REVEAL CONFORMATIONAL CHANGES RELEVANT TO REMARK 1 TITL 3 THE DESIGN OF POTENT NON-NUCLEOSIDE INHIBITORS REMARK 1 REF J.MED.CHEM. V. 39 1589 1996 REMARK 1 REFN ISSN 0022-2623 REMARK 1 DOI 10.1021/JM960056X REMARK 1 REFERENCE 13 REMARK 1 AUTH J.REN,R.M.ESNOUF,A.L.HOPKINS,C.K.ROSS,E.Y.JONES, REMARK 1 AUTH 2 D.K.STAMMERS,D.I.STUART REMARK 1 TITL THE STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE COMPLEXED WITH REMARK 1 TITL 2 9-CHLORO-TIBO: LESSONS FOR INHIBITOR DESIGN REMARK 1 REF STRUCTURE V. 3 915 1995 REMARK 1 REFN ISSN 0969-2126 REMARK 1 REFERENCE 14 REMARK 1 AUTH J.REN,R.M.ESNOUF,E.GARMAN,D.O.SOMERS,C.K.ROSS,I.KIRBY, REMARK 1 AUTH 2 J.KEELING,G.DARBY,E.Y.JONES,D.I.STUART,D.K.STAMMERS REMARK 1 TITL HIGH RESOLUTION STRUCTURES OF HIV-1 RT FROM FOUR REMARK 1 TITL 2 RT-INHIBITOR COMPLEXES REMARK 1 REF NAT.STRUCT.BIOL. V. 2 293 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 15 REMARK 1 AUTH R.M.ESNOUF,J.REN,C.K.ROSS,E.Y.JONES,D.K.STAMMERS,D.I.STUART REMARK 1 TITL MECHANISM OF INHIBITION OF HIV-1 REVERSE TRANSCRIPTASE BY REMARK 1 TITL 2 NON-NUCLEOSIDE INHIBITORS REMARK 1 REF NAT.STRUCT.BIOL. V. 2 303 1995 REMARK 1 REFN ISSN 1072-8368 REMARK 1 REFERENCE 16 REMARK 1 AUTH D.K.STAMMERS,D.O.SOMERS,C.K.ROSS,I.KIRBY,P.H.RAY,J.E.WILSON, REMARK 1 AUTH 2 M.NORMAN,J.REN,R.M.ESNOUF,E.GARMAN,E.Y.JONES,D.I.STUART REMARK 1 TITL CRYSTALS OF HIV-1 REVERSE TRANSCRIPTASE DIFFRACTING TO 2.2 A REMARK 1 TITL 2 RESOLUTION REMARK 1 REF J.MOL.BIOL. V. 242 586 1994 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.1994.1604 REMARK 2 REMARK 2 RESOLUTION. 2.62 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.62 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.80 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 2144345.600 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 87.2 REMARK 3 NUMBER OF REFLECTIONS : 28350 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.215 REMARK 3 FREE R VALUE : 0.279 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1437 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.62 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.71 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 77.10 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2337 REMARK 3 BIN R VALUE (WORKING SET) : 0.3140 REMARK 3 BIN FREE R VALUE : 0.3880 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.00 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 123 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.035 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7494 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 30 REMARK 3 SOLVENT ATOMS : 18 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 68.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 77.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -7.43000 REMARK 3 B22 (A**2) : -6.41000 REMARK 3 B33 (A**2) : 13.84000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.45 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.45 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.011 REMARK 3 BOND ANGLES (DEGREES) : 1.600 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 24.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.090 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 4.740 ; 4.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 7.770 ; 8.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 8.300 ; 6.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 12.750; 12.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.33 REMARK 3 BSOL : 46.96 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 3 : NEVIRAPINE.PARAM REMARK 3 PARAMETER FILE 4 : ION.PARAM REMARK 3 PARAMETER FILE 5 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : WATER_REP.TOP REMARK 3 TOPOLOGY FILE 3 : NEVIRAPINE.TOP REMARK 3 TOPOLOGY FILE 4 : ION.TOP REMARK 3 TOPOLOGY FILE 5 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1LWC COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 11-JUN-02. REMARK 100 THE DEPOSITION ID IS D_1000016342. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-JUN-98 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9903 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MAR SCANNER 345 MM PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28631 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.620 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -1.500 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.8 REMARK 200 DATA REDUNDANCY : 4.700 REMARK 200 R MERGE (I) : 0.07500 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 17.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.62 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.71 REMARK 200 COMPLETENESS FOR SHELL (%) : 71.6 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.000 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.81 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.27 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 5.00, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 70.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 32.65000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.60000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 32.65000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 70.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.60000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: HIV-1 RT IS A HETERODIMER CONSISTING OF A P66 AND A P51 REMARK 300 SUBUNITS, THE P51 CONTAINS THE FIRST 440 RESIDUES OF THE P66. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5710 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 43820 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -40.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 PRO A 1 REMARK 465 ILE A 2 REMARK 465 SER A 3 REMARK 465 ILE A 63 REMARK 465 LYS A 64 REMARK 465 LYS A 65 REMARK 465 LYS A 66 REMARK 465 ASP A 67 REMARK 465 SER A 68 REMARK 465 THR A 69 REMARK 465 LYS A 70 REMARK 465 TRP A 71 REMARK 465 ARG A 72 REMARK 465 GLU A 138 REMARK 465 THR A 139 REMARK 465 GLY A 444 REMARK 465 ALA A 445 REMARK 465 ALA A 446 REMARK 465 ASN A 447 REMARK 465 ARG A 448 REMARK 465 GLU A 449 REMARK 465 THR A 450 REMARK 465 LYS A 451 REMARK 465 LEU A 452 REMARK 465 GLY A 453 REMARK 465 LYS A 454 REMARK 465 THR A 468 REMARK 465 LEU A 469 REMARK 465 THR A 470 REMARK 465 ASP A 471 REMARK 465 ALA A 538 REMARK 465 HIS A 539 REMARK 465 LYS A 540 REMARK 465 GLY A 541 REMARK 465 ILE A 542 REMARK 465 GLY A 543 REMARK 465 GLY A 544 REMARK 465 ASN A 545 REMARK 465 GLU A 546 REMARK 465 GLN A 547 REMARK 465 VAL A 548 REMARK 465 ASP A 549 REMARK 465 LYS A 550 REMARK 465 LEU A 551 REMARK 465 VAL A 552 REMARK 465 SER A 553 REMARK 465 ALA A 554 REMARK 465 GLY A 555 REMARK 465 ILE A 556 REMARK 465 ARG A 557 REMARK 465 LYS A 558 REMARK 465 VAL A 559 REMARK 465 LEU A 560 REMARK 465 PRO B 1 REMARK 465 ILE B 2 REMARK 465 SER B 3 REMARK 465 PRO B 4 REMARK 465 ILE B 5 REMARK 465 GLU B 89 REMARK 465 VAL B 90 REMARK 465 GLN B 91 REMARK 465 LEU B 92 REMARK 465 GLY B 93 REMARK 465 LEU B 214 REMARK 465 THR B 215 REMARK 465 THR B 216 REMARK 465 PRO B 217 REMARK 465 ASP B 218 REMARK 465 LYS B 219 REMARK 465 LYS B 220 REMARK 465 HIS B 221 REMARK 465 GLN B 222 REMARK 465 LYS B 223 REMARK 465 GLU B 224 REMARK 465 MET B 357 REMARK 465 ARG B 358 REMARK 465 GLY B 359 REMARK 465 ALA B 360 REMARK 465 HIS B 361 REMARK 465 LEU B 429 REMARK 465 GLU B 430 REMARK 465 LYS B 431 REMARK 465 GLU B 432 REMARK 465 PRO B 433 REMARK 465 ILE B 434 REMARK 465 VAL B 435 REMARK 465 GLY B 436 REMARK 465 ALA B 437 REMARK 465 GLU B 438 REMARK 465 THR B 439 REMARK 465 PHE B 440 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 THR B 7 N - CA - C ANGL. DEV. = 16.4 DEGREES REMARK 500 PRO B 52 C - N - CA ANGL. DEV. = 9.1 DEGREES REMARK 500 TYR B 232 N - CA - C ANGL. DEV. = 16.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 6 139.50 -39.08 REMARK 500 GLN A 85 172.56 -57.25 REMARK 500 GLU A 89 109.03 -32.13 REMARK 500 GLN A 91 81.56 32.08 REMARK 500 LEU A 92 -71.17 -53.95 REMARK 500 ARG A 125 -38.22 -38.98 REMARK 500 GLU A 169 -56.97 -25.76 REMARK 500 PRO A 170 -74.07 -51.67 REMARK 500 ASN A 175 56.04 -146.18 REMARK 500 VAL A 184 -106.41 63.30 REMARK 500 ARG A 211 4.21 -57.44 REMARK 500 PRO A 225 144.82 -38.53 REMARK 500 THR A 240 -176.36 -178.53 REMARK 500 PRO A 243 118.43 -30.42 REMARK 500 ILE A 270 -34.70 -142.02 REMARK 500 LYS A 311 -37.20 -35.58 REMARK 500 PRO A 321 -8.57 -59.91 REMARK 500 PRO A 345 127.65 -29.87 REMARK 500 PHE A 346 -6.23 57.87 REMARK 500 THR A 362 -179.20 -172.02 REMARK 500 PRO A 392 47.08 -84.90 REMARK 500 PRO A 412 -159.97 -54.32 REMARK 500 LYS A 465 119.83 -162.82 REMARK 500 TYR A 501 -70.30 -64.44 REMARK 500 PRO B 14 121.81 -35.23 REMARK 500 PRO B 95 158.18 -33.92 REMARK 500 PHE B 116 9.94 -68.68 REMARK 500 ILE B 167 -8.31 -59.88 REMARK 500 ASN B 175 48.59 -156.94 REMARK 500 PRO B 176 17.90 -66.88 REMARK 500 VAL B 184 -127.92 55.07 REMARK 500 HIS B 198 -71.03 -63.66 REMARK 500 TRP B 212 26.60 -140.36 REMARK 500 MET B 230 -128.66 58.84 REMARK 500 ILE B 270 -67.69 -94.06 REMARK 500 PHE B 346 -17.04 76.75 REMARK 500 LYS B 347 76.60 -102.99 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A 1300 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PO4 A 1301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NVP A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1VRT RELATED DB: PDB REMARK 900 1VRT CONTAINS THE SAME PROTEIN COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1RTH RELATED DB: PDB REMARK 900 1RTH CONTAINS THE SAME PROTEIN COMPLEXED WITH 1051U91 REMARK 900 RELATED ID: 1VRU RELATED DB: PDB REMARK 900 1VRU CONTAINS THE SAME PROTEIN COMPLEXED WITH ALPHA-APA REMARK 900 RELATED ID: 1RTI RELATED DB: PDB REMARK 900 1RTI CONTAINS THE SAME PROTEIN COMPLEXED WITH HEPT REMARK 900 RELATED ID: 1RTJ RELATED DB: PDB REMARK 900 1RTJ CONTAINS THE SAME PROTEIN REMARK 900 RELATED ID: 1REV RELATED DB: PDB REMARK 900 1REV CONTAINS THE SAME PROTEIN COMPLEXED WITH 9-CL-TIBO REMARK 900 RELATED ID: 1RT1 RELATED DB: PDB REMARK 900 1RT1 CONTAINS THE SAME PROTEIN COMPLEXED WITH MKC-442 REMARK 900 RELATED ID: 1RT2 RELATED DB: PDB REMARK 900 1RT2 CONTAINS THE SAME PROTEIN COMPLEXED WITH TNK-651 REMARK 900 RELATED ID: 1KLM RELATED DB: PDB REMARK 900 1KLM CONTAINS THE SAME PROTEIN COMPLEXED WITH BHAP (U-90152) REMARK 900 RELATED ID: 1RT3 RELATED DB: PDB REMARK 900 1RT3 CONTAINS AZT DRUG RESISTANT HIV-1 RT MUTANT (RTMC) COMPLEXED REMARK 900 WITH 1051U91 REMARK 900 RELATED ID: 1RT4 RELATED DB: PDB REMARK 900 1RT4 CONTAINS THE SAME PROTEIN COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1RT5 RELATED DB: PDB REMARK 900 1RT5 CONTAINS THE SAME PROTEIN COMPLEXED WITH UC-10 REMARK 900 RELATED ID: 1RT6 RELATED DB: PDB REMARK 900 1RT6 CONTAINS THE SAME PROTEIN COMPLEXED WITH UC-38 REMARK 900 RELATED ID: 1RT7 RELATED DB: PDB REMARK 900 1RT7 CONTAINS THE SAME PROTEIN COMPLEXED WITH UC-84 REMARK 900 RELATED ID: 1C0T RELATED DB: PDB REMARK 900 1C0T CONTAINS THE SAME PROTEIN COMPLEXED WITH BM+21.1326 REMARK 900 RELATED ID: 1C0U RELATED DB: PDB REMARK 900 1C0U CONTAINS THE SAME PROTEIN COMPLEXED WITH BM+50.0934 REMARK 900 RELATED ID: 1C1B RELATED DB: PDB REMARK 900 1C1B CONTAINS THE SAME PROTEIN COMPLEXED WITH GCA-186 REMARK 900 RELATED ID: 1C1C RELATED DB: PDB REMARK 900 1C1C CONTAINS THE SAME PROTEIN COMPLEXED WITH TNK-6123 REMARK 900 RELATED ID: 1DTQ RELATED DB: PDB REMARK 900 1DTQ CONTAINS THE SAME PROTEIN COMPLEXED WITH PETT-1 REMARK 900 RELATED ID: 1DTT RELATED DB: PDB REMARK 900 1DTT CONTAINS THE SAME PROTEIN COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1EP4 RELATED DB: PDB REMARK 900 1EP4 CONTAINS THE SAME PROTEIN COMPLEXED WITH S-1153 REMARK 900 RELATED ID: 1FK9 RELATED DB: PDB REMARK 900 1FK9 CONTAINS THE SAME PROTEIN COMPLEXED WITH DMP-226 (EFAVIRENZ) REMARK 900 RELATED ID: 1FKO RELATED DB: PDB REMARK 900 1FKO CONTAINS K103N MUTANT HIV-1 RT COMPLEXED WITH DMP-226 REMARK 900 (EFAVIRENZ) REMARK 900 RELATED ID: 1FKP RELATED DB: PDB REMARK 900 1FKP CONTAINS K103N MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLA RELATED DB: PDB REMARK 900 1JLA CONTAINS Y181C MUTANT HIV-1 RT COMPLEXED TNK-651 REMARK 900 RELATED ID: 1JLB RELATED DB: PDB REMARK 900 1JLB CONTAINS Y181C MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLC RELATED DB: PDB REMARK 900 1JLC CONTAINS Y181C MUTANT HIV-1 RT COMPLEXED WITH PETT-2 REMARK 900 RELATED ID: 1JLE RELATED DB: PDB REMARK 900 1JLE CONTAINS Y188C MUTANT HIV-1 RT REMARK 900 RELATED ID: 1JLF RELATED DB: PDB REMARK 900 1JLF CONTAINS Y188C MUTANT HIV-1 RT COMPLEXED WITH NEVIRAPINE REMARK 900 RELATED ID: 1JLG RELATED DB: PDB REMARK 900 1JLG CONTAINS Y188C MUTANT HIV-1 RT COMPLEXED WITH UC-781 REMARK 900 RELATED ID: 1JKH RELATED DB: PDB REMARK 900 1JKH CONTAINS Y181C MUTANT HIV-1 RT COMPLEXED WITH DMP-226 REMARK 900 (EFAVIRENZ) REMARK 900 RELATED ID: 1JLQ RELATED DB: PDB REMARK 900 1JLQ CONTAINS THE SAME PROTEIN COMPLEXED WITH 739W94 REMARK 900 RELATED ID: 1LW0 RELATED DB: PDB REMARK 900 1LW0 CONTAINS T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX REMARK 900 WITH NEVIRAPINE REMARK 900 RELATED ID: 1LW2 RELATED DB: PDB REMARK 900 1LW2 CONTAINS T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX REMARK 900 WITH 1051U91 REMARK 900 RELATED ID: 1LWE RELATED DB: PDB REMARK 900 1LWE CONTAINS M41L/T215Y MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMN) REMARK 900 IN COMPLEX WITH NEVIRAPINE REMARK 900 RELATED ID: 1LWF RELATED DB: PDB REMARK 900 1LWF CONTAINS MUTANT HIV-1 REVERSE TRANSCRIPTASE (RTMQ+M184V: M41L/ REMARK 900 D67N/K70R/M184V/T215Y) IN COMPLEX WITH NEVIRAPINE DBREF 1LWC A 1 560 UNP P04585 POL_HV1H2 156 715 DBREF 1LWC B 1 440 UNP P04585 POL_HV1H2 156 595 SEQADV 1LWC VAL A 184 UNP P04585 MET 339 ENGINEERED MUTATION SEQADV 1LWC CSD A 280 UNP P04585 CYS 435 MODIFIED RESIDUE SEQADV 1LWC VAL B 184 UNP P04585 MET 339 ENGINEERED MUTATION SEQRES 1 A 560 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 A 560 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 A 560 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 A 560 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 A 560 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 A 560 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 A 560 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 A 560 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 A 560 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 A 560 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 A 560 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 A 560 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 A 560 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 A 560 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 A 560 TYR VAL ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 A 560 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 A 560 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 A 560 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 A 560 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 A 560 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 A 560 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 A 560 ILE LYS VAL ARG GLN LEU CSD LYS LEU LEU ARG GLY THR SEQRES 23 A 560 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 A 560 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 A 560 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 A 560 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 A 560 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 A 560 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 A 560 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 A 560 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 A 560 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 A 560 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 A 560 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 A 560 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE TYR VAL SEQRES 35 A 560 ASP GLY ALA ALA ASN ARG GLU THR LYS LEU GLY LYS ALA SEQRES 36 A 560 GLY TYR VAL THR ASN ARG GLY ARG GLN LYS VAL VAL THR SEQRES 37 A 560 LEU THR ASP THR THR ASN GLN LYS THR GLU LEU GLN ALA SEQRES 38 A 560 ILE TYR LEU ALA LEU GLN ASP SER GLY LEU GLU VAL ASN SEQRES 39 A 560 ILE VAL THR ASP SER GLN TYR ALA LEU GLY ILE ILE GLN SEQRES 40 A 560 ALA GLN PRO ASP GLN SER GLU SER GLU LEU VAL ASN GLN SEQRES 41 A 560 ILE ILE GLU GLN LEU ILE LYS LYS GLU LYS VAL TYR LEU SEQRES 42 A 560 ALA TRP VAL PRO ALA HIS LYS GLY ILE GLY GLY ASN GLU SEQRES 43 A 560 GLN VAL ASP LYS LEU VAL SER ALA GLY ILE ARG LYS VAL SEQRES 44 A 560 LEU SEQRES 1 B 440 PRO ILE SER PRO ILE GLU THR VAL PRO VAL LYS LEU LYS SEQRES 2 B 440 PRO GLY MET ASP GLY PRO LYS VAL LYS GLN TRP PRO LEU SEQRES 3 B 440 THR GLU GLU LYS ILE LYS ALA LEU VAL GLU ILE CYS THR SEQRES 4 B 440 GLU MET GLU LYS GLU GLY LYS ILE SER LYS ILE GLY PRO SEQRES 5 B 440 GLU ASN PRO TYR ASN THR PRO VAL PHE ALA ILE LYS LYS SEQRES 6 B 440 LYS ASP SER THR LYS TRP ARG LYS LEU VAL ASP PHE ARG SEQRES 7 B 440 GLU LEU ASN LYS ARG THR GLN ASP PHE TRP GLU VAL GLN SEQRES 8 B 440 LEU GLY ILE PRO HIS PRO ALA GLY LEU LYS LYS LYS LYS SEQRES 9 B 440 SER VAL THR VAL LEU ASP VAL GLY ASP ALA TYR PHE SER SEQRES 10 B 440 VAL PRO LEU ASP GLU ASP PHE ARG LYS TYR THR ALA PHE SEQRES 11 B 440 THR ILE PRO SER ILE ASN ASN GLU THR PRO GLY ILE ARG SEQRES 12 B 440 TYR GLN TYR ASN VAL LEU PRO GLN GLY TRP LYS GLY SER SEQRES 13 B 440 PRO ALA ILE PHE GLN SER SER MET THR LYS ILE LEU GLU SEQRES 14 B 440 PRO PHE ARG LYS GLN ASN PRO ASP ILE VAL ILE TYR GLN SEQRES 15 B 440 TYR VAL ASP ASP LEU TYR VAL GLY SER ASP LEU GLU ILE SEQRES 16 B 440 GLY GLN HIS ARG THR LYS ILE GLU GLU LEU ARG GLN HIS SEQRES 17 B 440 LEU LEU ARG TRP GLY LEU THR THR PRO ASP LYS LYS HIS SEQRES 18 B 440 GLN LYS GLU PRO PRO PHE LEU TRP MET GLY TYR GLU LEU SEQRES 19 B 440 HIS PRO ASP LYS TRP THR VAL GLN PRO ILE VAL LEU PRO SEQRES 20 B 440 GLU LYS ASP SER TRP THR VAL ASN ASP ILE GLN LYS LEU SEQRES 21 B 440 VAL GLY LYS LEU ASN TRP ALA SER GLN ILE TYR PRO GLY SEQRES 22 B 440 ILE LYS VAL ARG GLN LEU CYS LYS LEU LEU ARG GLY THR SEQRES 23 B 440 LYS ALA LEU THR GLU VAL ILE PRO LEU THR GLU GLU ALA SEQRES 24 B 440 GLU LEU GLU LEU ALA GLU ASN ARG GLU ILE LEU LYS GLU SEQRES 25 B 440 PRO VAL HIS GLY VAL TYR TYR ASP PRO SER LYS ASP LEU SEQRES 26 B 440 ILE ALA GLU ILE GLN LYS GLN GLY GLN GLY GLN TRP THR SEQRES 27 B 440 TYR GLN ILE TYR GLN GLU PRO PHE LYS ASN LEU LYS THR SEQRES 28 B 440 GLY LYS TYR ALA ARG MET ARG GLY ALA HIS THR ASN ASP SEQRES 29 B 440 VAL LYS GLN LEU THR GLU ALA VAL GLN LYS ILE THR THR SEQRES 30 B 440 GLU SER ILE VAL ILE TRP GLY LYS THR PRO LYS PHE LYS SEQRES 31 B 440 LEU PRO ILE GLN LYS GLU THR TRP GLU THR TRP TRP THR SEQRES 32 B 440 GLU TYR TRP GLN ALA THR TRP ILE PRO GLU TRP GLU PHE SEQRES 33 B 440 VAL ASN THR PRO PRO LEU VAL LYS LEU TRP TYR GLN LEU SEQRES 34 B 440 GLU LYS GLU PRO ILE VAL GLY ALA GLU THR PHE MODRES 1LWC CSD A 280 CYS 3-SULFINOALANINE HET CSD A 280 8 HET PO4 A1300 5 HET PO4 A1301 5 HET NVP A 999 20 HETNAM CSD 3-SULFINOALANINE HETNAM PO4 PHOSPHATE ION HETNAM NVP 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2- HETNAM 2 NVP B:2',3'-E][1,4]DIAZEPIN-6-ONE HETSYN CSD S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE HETSYN NVP NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE FORMUL 1 CSD C3 H7 N O4 S FORMUL 3 PO4 2(O4 P 3-) FORMUL 5 NVP C15 H14 N4 O FORMUL 6 HOH *18(H2 O) HELIX 1 1 THR A 27 GLU A 44 1 18 HELIX 2 2 PHE A 77 THR A 84 1 8 HELIX 3 3 HIS A 96 LEU A 100 5 5 HELIX 4 4 ALA A 114 VAL A 118 5 5 HELIX 5 5 PHE A 124 THR A 128 5 5 HELIX 6 6 GLY A 155 GLN A 174 1 20 HELIX 7 7 GLU A 194 ARG A 211 1 18 HELIX 8 8 ASP A 218 GLN A 222 5 5 HELIX 9 9 VAL A 254 SER A 268 1 15 HELIX 10 10 VAL A 276 LYS A 281 1 6 HELIX 11 11 LEU A 282 ARG A 284 5 3 HELIX 12 12 THR A 296 GLU A 312 1 17 HELIX 13 13 ASN A 363 GLY A 384 1 22 HELIX 14 14 GLN A 394 GLU A 404 1 11 HELIX 15 15 THR A 473 SER A 489 1 17 HELIX 16 16 SER A 499 ALA A 508 1 10 HELIX 17 17 SER A 515 LYS A 528 1 14 HELIX 18 18 THR B 27 GLU B 44 1 18 HELIX 19 19 PHE B 77 THR B 84 1 8 HELIX 20 20 GLY B 99 LYS B 103 5 5 HELIX 21 21 GLY B 112 VAL B 118 5 7 HELIX 22 22 PHE B 124 ALA B 129 5 6 HELIX 23 23 SER B 134 GLU B 138 5 5 HELIX 24 24 LYS B 154 ASN B 175 1 22 HELIX 25 25 GLU B 194 ARG B 211 1 18 HELIX 26 26 HIS B 235 TRP B 239 5 5 HELIX 27 27 THR B 253 SER B 268 1 16 HELIX 28 28 VAL B 276 LEU B 282 1 7 HELIX 29 29 THR B 296 LYS B 311 1 16 HELIX 30 30 ASN B 363 GLY B 384 1 22 HELIX 31 31 GLN B 394 TRP B 406 1 13 HELIX 32 32 PRO B 420 TRP B 426 1 7 SHEET 1 A 3 ILE A 47 LYS A 49 0 SHEET 2 A 3 ILE A 142 TYR A 146 -1 O GLN A 145 N SER A 48 SHEET 3 A 3 PHE A 130 ILE A 132 -1 N ILE A 132 O ILE A 142 SHEET 1 B 2 VAL A 60 PHE A 61 0 SHEET 2 B 2 LEU A 74 VAL A 75 -1 O LEU A 74 N PHE A 61 SHEET 1 C 3 SER A 105 VAL A 108 0 SHEET 2 C 3 ASP A 186 SER A 191 -1 O VAL A 189 N THR A 107 SHEET 3 C 3 VAL A 179 TYR A 183 -1 N TYR A 181 O TYR A 188 SHEET 1 D 4 PHE A 227 TRP A 229 0 SHEET 2 D 4 TYR A 232 LEU A 234 -1 O TYR A 232 N TRP A 229 SHEET 3 D 4 LYS A 238 VAL A 241 -1 O THR A 240 N GLU A 233 SHEET 4 D 4 GLY A 316 VAL A 317 -1 O GLY A 316 N TRP A 239 SHEET 1 E 2 TRP A 252 THR A 253 0 SHEET 2 E 2 VAL A 292 ILE A 293 -1 O ILE A 293 N TRP A 252 SHEET 1 F 5 LYS A 347 TYR A 354 0 SHEET 2 F 5 GLN A 336 GLU A 344 -1 N ILE A 341 O LYS A 350 SHEET 3 F 5 ILE A 326 GLY A 333 -1 N ILE A 326 O TYR A 342 SHEET 4 F 5 LYS A 388 LEU A 391 1 O LYS A 388 N ALA A 327 SHEET 5 F 5 TRP A 414 PHE A 416 1 O GLU A 415 N PHE A 389 SHEET 1 G 2 HIS A 361 THR A 362 0 SHEET 2 G 2 GLN A 512 SER A 513 -1 O GLN A 512 N THR A 362 SHEET 1 H 5 GLN A 464 VAL A 466 0 SHEET 2 H 5 GLY A 456 THR A 459 -1 N TYR A 457 O LYS A 465 SHEET 3 H 5 THR A 439 VAL A 442 -1 N TYR A 441 O VAL A 458 SHEET 4 H 5 GLU A 492 THR A 497 1 O VAL A 496 N PHE A 440 SHEET 5 H 5 LYS A 530 TRP A 535 1 O TYR A 532 N ILE A 495 SHEET 1 I 3 ILE B 47 LYS B 49 0 SHEET 2 I 3 ILE B 142 TYR B 146 -1 O GLN B 145 N SER B 48 SHEET 3 I 3 PHE B 130 ILE B 132 -1 N ILE B 132 O ILE B 142 SHEET 1 J 2 VAL B 60 LYS B 64 0 SHEET 2 J 2 TRP B 71 VAL B 75 -1 O ARG B 72 N ILE B 63 SHEET 1 K 4 VAL B 179 TYR B 183 0 SHEET 2 K 4 ASP B 186 SER B 191 -1 O TYR B 188 N TYR B 181 SHEET 3 K 4 SER B 105 ASP B 110 -1 N LEU B 109 O LEU B 187 SHEET 4 K 4 PHE B 227 LEU B 234 -1 O LEU B 228 N VAL B 108 SHEET 1 L 5 LYS B 347 ALA B 355 0 SHEET 2 L 5 GLN B 336 GLU B 344 -1 N ILE B 341 O LEU B 349 SHEET 3 L 5 ILE B 326 GLY B 333 -1 N ILE B 326 O TYR B 342 SHEET 4 L 5 LYS B 388 LEU B 391 1 O LYS B 388 N ALA B 327 SHEET 5 L 5 GLU B 413 PHE B 416 1 O GLU B 415 N LEU B 391 LINK C LEU A 279 N CSD A 280 1555 1555 1.33 LINK C CSD A 280 N LYS A 281 1555 1555 1.33 CISPEP 1 PRO A 225 PRO A 226 0 -0.12 CISPEP 2 PRO A 420 PRO A 421 0 -0.05 SITE 1 AC1 2 ARG A 461 LYS B 13 SITE 1 AC2 6 GLY A 436 ALA A 437 GLU A 438 ASN A 460 SITE 2 AC2 6 ARG A 461 ALA B 288 SITE 1 AC3 11 LEU A 100 LYS A 101 LYS A 103 VAL A 106 SITE 2 AC3 11 VAL A 179 TYR A 181 TYR A 188 GLY A 190 SITE 3 AC3 11 HIS A 235 PRO A 236 TYR A 318 CRYST1 140.000 115.200 65.300 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.007143 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008681 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015314 0.00000